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Summary
Breast cancer–susceptibility genes BRCA1 and BRCA2
have recently been identified on the human genome.
Women who carry a mutation of one of these genes have
a greatly increased chance of developing breast and ovar-
ian cancer, and they usually develop the disease at a
much younger age, compared with normal individuals.
Women can be tested to see whether they are carriers.
A woman who undergoes genetic counseling before test-
ing can be told the probabilities that she is a carrier,
given her family history. In this paper we develop a
model for evaluating the probabilities that a woman is
a carrier of a mutation of BRCA1 and BRCA2, on the
basis of her family history of breast and ovarian cancer
in first- and second-degree relatives. Of special impor-
tance are the relationships of the family members with
cancer, the ages at onset of the diseases, and the ages of
family members who do not have the diseases. This in-
formation can be elicited during genetic counseling and
prior to genetic testing. The carrier probabilities are ob-
tained from Bayes’s rule, by use of family history as the
evidence and by use of the mutation prevalences as the
prior distribution. In addressing an individual’s carrier
probabilities, we incorporate uncertainty about some of
the key inputs of the model, such as the age-specific
incidence of diseases and the overall prevalence of mu-
tations. There is some evidence that other, undiscovered
genes may be important in explaining familial breast
cancer. Users of the current version of the model should
be aware of this limitation. The methodology that we
describe can be extended to more than two genes, should
data become available about other genes.
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Introduction
Recent years have marked important progress in our
understanding of inherited susceptibility to breast can-
cer, with the identifications of the BRCA1 and BRCA2
genes (Futreal et al. 1994; Miki et al. 1994; Wooster et
al. 1995; Szabo and King 1997). Inherited mutation of
one of these genes results in making its carriers at a much
increased risk of developing breast cancer as well as
ovarian cancer. It has become possible and increasingly
common to test for the presence of these mutations. Al-
though the availability of testing represents a major op-
portunity both scientifically and clinically, it also creates
important challenges for women facing the testing de-
cision and for physicians and genetic counselors inter-
ested in helping women to understand risks of breast
cancer and available preventive options (Hoskins et al.
1995). The chance of carrying a genetic mutation varies
markedly from woman to woman, depending on family
history of breast cancer and related cancers. As a result,
increasing attention needs to be given to understanding
and conveying risk information in an individualizedway.
In this context, risk-prediction algorithms that fully ex-
plicitate our knowledge about the nature of the inheri-
tance mechanism can contribute in an important way to
a woman’s decision.
Testing for BRCA1 and BRCA2 mutations is expen-
sive (currently the cost is $2,400 for both genes), and a
positive outcome can affect a person’s life in important
ways: in eligibility for health insurance and in potential
employment discrimination, as well as in physical and
psychological aspects. A positive test or simply the per-
ception of a high risk can lead to aggressive manage-
ment, ranging from more-frequent mammographies to
bilateral mastectomy, again with substantive conse-
quences on a woman’s life. A crucial step in counseling
a women facing these decisions is an accurate evaluation
of the probability that she carries a mutation. Also, after
the test(s) is performed, the relevant calculation for de-
cision making is the posterior probability of mutation,
given the outcome of the test. Accurate assessment of
these probabilities requires accurate prior input.
The purpose of this article is to describe a method for
finding the probability that a particular family member
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(the counseland) carries a germ-line mutation at BRCA1
or BRCA2, on the basis of her family’s history of breast
cancer and ovarian cancer. Although the method applies
to both women and men, the counseland is usually fe-
male. The family history includes the counseland and
her first- and second-degree relatives. For each member,
we ascertain both whether he or she has been diagnosed
with breast cancer and either the age at diagnosis or, if
cancer free, the current age or the age at death; we follow
a similar procedure for ovarian cancer, if the member is
female.
Other models have addressed the risk of breast cancer
for women with a family history of the disease (Gail et
al. 1989; Claus et al. 1994; Houwing-Duistermaat and
Van Houwelingen 1997). Although useful, none of these
models directly addresses the probability that the
woman carries a mutation at BRCA1 or BRCA2, as is
needed in genetic counseling and genetic-testing deci-
sions. Shattuck-Eidens et al. (1995) have provided a
summary table of estimated probabilities of carrying a
BRCA1 mutation, for 11 categories of high-risk women.
A logistic-regression approach has been proposed by
Couch et al. (1997). These models use summary meas-
ures of family history, such as the number of affected
relatives. A woman with given numbers of first- and
second-degree relatives with breast cancer and/or ovar-
ian cancer can have a wide range of probability of mu-
tation, depending on the pedigree structure, the exact
relationship of the affected members, and the family size.
In practical counseling situations, it can be important to
account for these fully.
We use basic Bayesian methods to incorporate all rel-
evant family history, up to second-degree relatives. In
addition, we incorporate uncertainty in the inputs. We
proceed by computing a likelihood ratio for the observed
family history. An estimate of the mutation frequency
in the population provides the probability of a mutation
in the counseland, prior to the ascertainment of family
history. Bayes’s rule applies to determination of the
probability of a mutation, given family history. This
probability is posterior to family history but is prior to
genetic testing. Calculation of the likelihood is per-
formed by use of analytic expressions, for given values
of the model parameters. These are evaluated by use of
software developed, in the C programming language,
expressly for this project, since none of the publically
available linkage-analysis software packages can handle
risk predictions for mutations of two genes each of
which leads to different penetrance functions for two
different diseases. Uncertainty about the model para-
meters is addressed by use of a Monte Carlo simulation,
programmed by means of the statistical package S-plus.
The relevance of Bayesian calculations for genetic
counseling has been recognized for a long time (Murphy
and Mutalik 1969). The use of likelihood ratios in ped-
igree analysis is also well established (Thompson 1986;
Thompson and Guo 1991). The use of Bayesian tech-
niques in software, for determination of the positive pre-
dictive power of family history, has a precedent in the
work of Szolovits and Pauker (1992). A likelihood-ap-
proach alternative to ours, for incorporation of uncer-
tainty in the estimates of genetic parameters, has been
discussed in the work of Leal and Ott (1994). The clin-
ical implications of our probability calculations for
BRCA1 only have been developed in the work of Berry
et al. (1997).
The outline of this article is as follows. In theMethods
section, we introduce the notation, model assumptions,
and evidence regarding the population frequency of the
BRCA1 and BRCA2 mutations, as wll as the disease-
incidence functions associated with these mutations. In
the Results section, we present results for two family
histories that arise from clinical experience. In the Ap-
pendix, we give explicit expressions for the likelihood
ratio.
Methods
Definitions and Notation
In this section we establish the notation and review
the assumptions. We assume that individuals inherit two
BRCA1/BRCA2 alleles, one from each parent, and that
alleles are either normal or mutated; mutations are in-
herited independently. We assume an autosomal domi-
nant inheritance of mutations, empirically supported by
the analysis presented Claus et al. (1991).
At each locus, an individual can have zero, one, or
two mutations. Our model addresses the joint proba-
bility of a specific configuration of BRCA1 and BRCA2
genes, represented by a two-dimensional vector. We use
the notation to denote theP[BRCA1  i , BRCA2  i ]1 2
probability of the counseland having i1 mutated copies
of BRCA1, , and i2 mutated copies of BRCA2,i  0, 1, 21
.i  0, 1, 22
The frequencies of mutations in the allele population
are indicated by f1 and f2, for BRCA1 and BRCA2, re-
spectively. In the absence of information about disease
and family history, the probabilities that an individual
inherits a given number of mutated copies of BRCA1
are , ,2P[BRCA1  2]  f P[BRCA1  1]  f (1 f )1 1 1
and . The probability that an2P[BRCA1  0]  (1 f )1
individual carries at least one BRCA1 mutation is
. Of these individuals, the fraction2p  f  2f (1 f )1 1 1 1
carrying two mutations is therefore g  f / [f  2(11 1 1
. Similar expressions hold for BRCA2. Joint proba-f )]1
bilities can be obtained on the basis of independence.
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Updating
Our goal is to compute the joint probability distri-
bution of the BRCA1 and BRCA2 genetic-status vari-
ables of a woman, given her family history (subsequently
denoted as “fam.hist.” in mathematical expressions).
From Bayes’s rule,
P[BRCA1, BRCA2Ffam.hist.] 
P[BRCA1]P[BRCA2]P[fam.hist.FBRCA1,BRCA2]
P[fam.hist.]
(1)
Although the BRCA1 and BRCA2 variables can be as-
sumed to be independent a priori, they will typically not
be independent conditional on family history.
On the basis of the joint probability distribution aris-
ing from expression (1), we can compute various sum-
maries that are of interest in both decision making and
genetic testing. These include the probability, given her
family history, that a woman is a carrier of either a
BRCA1 mutation or a BRCA2 mutation,
∗p  1 P[BRCA1  0, BRCA2  0Ffam.hist.] ,
the marginal probabilities, given her family history, that
a woman is a carrier of BRCA1,
∗p { P[BRCA11
 1 or 2Ffam.hist.]
2 2
 P[BRCA1  i ,1
i 1 i 01 2
BRCA2  i Ffam.hist.] ,2
and the marginal probabilities , given her family his-∗p2
tory, that a woman is a carrier of BRCA2, obtained in
a manner similar to that given above.
Determining in expres-P[fam.hist.FBRCA1,BRCA2]
sion (1) can be computationally intensive. However,
there are three simple building blocks that underlie this
calculation: the probability of the genetic status of
offspring, given those of their parents; the probability
of the genetic status of parents, given those of their off-
spring; and the probability of disease outcome, given
genetic status. The first two are discussed next; the third
is discussed in the Evidence subsection.
In the Appendix, we show how to compute
.P[fam.hist.FBRCA1,BRCA2]
The probability of a configuration of the offsprings’
genetic status, given the genetic status of their parents,
is computed on the basis of random selection of each
offspring’s alleles from each parent’s two alleles (see Fal-
coner and Mckay 1996). We use the notation “o” to
designate the offspring’s genetic status, “m” to designate
the mother’s genetic status, and “f” to designate the
father’s genetic status. Each of these is a two-dimen-
sional vector. The two coordinates represent the number
of mutated alleles at BRCA1 and BRCA2, respectively.
The set of possible values is . Because{0, 1, 2} # {0, 1, 2}
inheritances of BRCA1 and BRCA2 mutations are as-
sumed to be a priori independent, we can focus on mar-
ginal distributions.
The probability of any joint configuration of the par-
ents’ genetic status, given that of one of their offspring,
requires a simple application of Bayes’s rule. We begin
by assuming independence between the genetic status of
the two parents, which is tenable when random mating
in the population is assumed. This implies P [m, f] 
, and, when Bayes’s rule is applied,P [m]P[f]
P[m]P[f ]P[oFm, f ]
P[m, fFo]  .P[m]P[f ]P[oFm, f ]
m f
Uncertainty about Genetic Parameters
From expression (1) we see that inference about the
genetic status of the counseland requires knowledge of
the mutation frequencies and of cancer rates for both
carriers and noncarriers of the mutations. These need to
be evaluated for all family members whose history of
breast cancer and ovarian cancer (including the lack of
such history) is available. These evaluations are based
on empirical studies and so are uncertain. Uncertainty
can be accommodated by a Bayesian approach, as fol-
lows. We denote by v the set of parameters indexing the
cancer-rate models, and we denote by
the probability distribution ex-P(v, f , f Fpublished data)1 2
pressing the uncertainty about (v,f1,f2), on the basis of
the published estimates.
We can then use to computeP(v, f , f Fpublished data)1 2
the distribution of the random variables
P[BRCA1, BRCA2Ffam.hist., v, f , f ]1 2
 {P[BRCA1, BRCA2Ff , f ]1 2
# P[fam.hist.FBRCA1, BRCA2, v, f , f ]}/1 2
# P[fam.hist.Fv, f , f ]1 2
with and . This hasBRCA1  0, 1, 2 BRCA2  0, 1, 2
the feature of examining separately the uncertainty de-
riving from the unknown genetic status of the family
members, which is integrated out, from the uncertainty
about the population rates and prevalence. Alternatively,
we can write the probability distribution of interest, in
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Figure 1 Cumulative rates of breast cancer (B) and ovarian (O)
cancer, for mutation carriers, for (top) BRCA1 (based on Easton et
al. 1995) and (bottom) BRCA2 (based on data of D. F. Easton, personal
communication). The lines indicate our interpolation, based on a three-
parameter gamma c.d.f, with one of the parameters being the asymp-
tote, which may be !1.
presence of estimation error, by integrating out the un-
known parameters:
P[BRCA1, BRCA2Ffam.hist.] 
P[BRCA1, BRCA2Ffam.hist., v, f , f ] 1 2
p(v, f , f Fpublished data)df df dv .1 2 1 2
We can evaluate the integrand ratio exactly (see the Ap-
pendix), and we perform the integration by means of
Monte Carlo methods.
A calculation of interest is the probability that an in-
dividual will develop breast cancer or ovarian cancer
later in life. This is straightforward and is a weighted
average of the corresponding probabilities for carriers
and noncarriers, when the posterior probabilities of be-
ing a carrier and a noncarrier are used as weights.
The impact that the allowance for error in the param-
eter estimates has, both on the carrier probabilities and
on the final risk estimates, will be illustrated in the Dis-
cussion section.
Evidence
In this section we discuss the empirical evidence about
cancer rates and mutation frequency that we will use in
our calculations. Easton et al. (1995) have discussed the
penetrance of breast cancer and ovarian cancer in
BRCA1 carriers, as a function of age. Figure 1 sum-
marizes the rates that they report; breast cancer rates
are indicated by a “B,” and ovarian cancer rates are
indicated by an “O.” The curves represent our inter-
polation. For BRCA1, ∼85% of female carriers will get
breast cancer, and ∼65% will get ovarian cancer, by the
age of 70 years. Apparently, these two cancers
occur independently among carriers. By age 70 years,
, or 95%, of carriers have one∼ 1 [(1 .85)(1 .65)]
disease or the other, and , or 55%, have both∼ .85 # .65
diseases. Similar multiplications apply for other ages.
Figure 1 also shows our interpolations of the rates
reported by Easton et al. (1995). The curves are based
on fitting a gamma CDF to the reported rates, by use
of nonlinear least squares after an arcsine transforma-
tion of the response. The asymptote (a) of the CDF is
a free parameter, allowed to be !1 in order to accom-
modate incomplete penetrance: not every carrier will de-
velop breast cancer or ovarian cancer. Formally, if a is
age and if R is the cumulative rate under consideration,
we assume that
a
nb
n1 xbR(a)  a x e dx .
G(n)0
Figure 1 also shows the results of the same type of in-
terpolations on the penetrance functions for BRCA2,
with data from D. F. Easton (personal communication;
also see Easton et al. 1997). Data on the penetrance
functions for male breast cancer are not available at this
time. We have assumed that the shape of the penetrance
function for male BRCA2 carriers is the same as that
for female BRCA2 carries but that it has a smaller as-
ymptote, .15. Penetrance functions for male BRCA1 car-
riers are assumed to be the same as those for normal
individuals.
Although it is rare, we need to consider the possibility
that an individual may carry mutations at both BRCA1
and BRCA2. No data are available concerning incidence
of disease among carriers of mutations at both genes. In
our model, their penetrance functions are determined as
the cumulative distribution of the minimum of two in-
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Figure 2 Number of breast cancer cases and ovarian cancer cases, for both BRCA1 and BRCA2 carriers and noncarriers. The scales for
carriers and noncarriers are different, for better resolution. All else being equal, ovarian cancer is a stronger indication of a mutation than is
breast cancer, and earlier-onset breast cancer is a stronger indication than is later-onset breast cancer.
dependent events: cancer due to BRCA1 and cancer due
to BRCA2. The results are not very sensitive to this
assumption.
The disease history for a family member can include
bilateral breast cancer. Estimation of rates of bilateral
recurrence is difficult, because of the lack of good data.
In the current version of our model, we approximate the
rates for bilateral recurrences by assuming that the ob-
served breast cancer rates R(a) represent the distribution
of the minimum of two independent events: cancer in
the left breast and cancer in the right breast. The cu-
mulative rates of the time to cancer in a particular breast
will then be . The likelihood for′ R (a)  1 1 R(a)
bilateral breast cancer cases that are diagnosed at ages
150 Am. J. Hum. Genet. 62:145–158, 1998
Figure 3 Probability distribution of penetrance functions. Each
graph is a sample of 30 penetrance curves. The upper two graphs refer
to BRCA1 carriers, and the lower two graphs refer to BRCA2 carriers.
Curves are interpreted as in figure 1. The uncertainty about the pen-
etrance of the mutation is captured by variability in the total number
of cases at age 80 years. The uncertainty about rates at young ages is
high, in relative terms.
Figure 5 Family history 1 of section 4. Age, when known, is
shown for each family member; it is either age at the time of the present
study or age at death.
Figure 6 Family history 2 of section 4. Age, when known, is
shown for each female family member; it is either her age at the time
of the assessment or her age at death. If there is no indication of breast
cancer or ovarian cancer, then the family member is free of both.
Figure 4 Assumed probability distributions of allele mutation
frequencies. The unbroken line is the distribution of f1, whereas the
broken line is the distribution of f2.
a1 and a2, with , will then be r
′(a1)r
′(a2), where r
′a X a1 2
is the derivative of R′. In addition to depending on age,
the likelihood of a bilateral recurrence can depend on
adjuvant treatment or preventive surgery administered
after the first primary cancer. These features are not in-
corporated here.
Cancer rates for normal individuals can be obtained
from epidemiological registries such as the SEER data
base. Moolgavkar et al. (1979) used SEER data to de-
velop a general model of incidence of breast cancer in
the female population. The model accounts for a cohort
effect and yields estimates of incidence and mortality as
a function of age. We have used the incidence functions
of Moolgavkar et al., together with life tables, to deter-
mine the breast cancer rates for the general population.
Subtraction of the estimated BRCA1/BRCA2 cases leads
to an age distribution for noncarriers. We have used a
similar strategy for ovarian cancer, on the basis of the
results reported by Yancik (1993). Figure 2 summarizes
estimated carrier rates and noncarrier rates, for breast
cancer and for ovarian cancer, in females. The graphs
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Table 1
Five Scenarios for Penetrance and Prevalence Parameters
SCENARIO
ALLELE
FREQUENCY
PENETRANCE AT AGE 110 YEARS
Breast Cancer Ovarian Cancer
f1 f2 BRCA1 BRCA2 BRCA1 BRCA2
1(Baseline) .0006 .00022 .90 .70 .75 .25
2 .0008 .00030 .95 .75 .85 .35
3 .00045 .000165 .95 .75 .85 .35
4 .0008 .00030 .70 .40 .60 .15
5 .00045 .000165 .70 .40 .60 .15
Table 2
Probability That Counseland of Family
1 Carries BRCA1 or BRCA2, in Five
Scenarios Given in Table 1
PROBABILITY
SCENARIO
∗pi BRCA1 BRCA2
1 .966 .589 .377
2 .978 .429 .549
3 .960 .427 .533
4 .966 .843 .123
5 .945 .827 .118
Figure 7 Probabilistic sensitivity analysis, family 1. Boxplots represent the distribution of the probability that family member 1 of family
1 carries a mutation of BRCA1 or BRCA2, with her age being allowed to change. We are considering the modified version of the pedigree, in
which the counseland’s father is assumed to have breast cancer and in which the mother is cancer free. Each boxplot is based on the same
Monte Carlo sample of size 100. The variability is due to uncertainty in the cancer rates and in the allele frequency.
represent the number of cases, per year, per 1,000
women. Carriers have a higher incidence and a higher
propensity to develop breast cancer at a young age.
We have incorporated uncertainty about the carrier
rates, as discussed in the Methods section. Easton et al.
(1995) have provided confidence intervals for the inci-
dence rates at age 50 years. On the basis of these, we
have assigned probability distributions to the penetrance
functions for breast cancer rates and ovarian cancer
rates. We have used beta distributions for the a para-
meters and have used Gaussian distributions for the n
and b parameters. To illustrate the implications of our
specifications, we have generated a sample of the re-
sulting curves; these are shown in figure 3.
The frequency of genetic mutations at BRCA1 has
been discussed by Ford and Easton (1995), who provide
a 95% confidence interval of .0002–.001. for f1. On the
basis of this, we have assigned a beta probability dis-
tribution on f1, with parameters 6.29 and 12,000, plac-
ing ∼95% of the mass on the interval (.0002–.001). The
prevalence of genetic mutations at BRCA2 has been re-
viewed by Andersen (1996). Uncertainty assessments are
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Table 3
Probability That Counseland of Family
1 Carries BRCA1 or BRCA2, in Five
Scenarios Given in Table 1
SCENARIO
PROBABILITY
∗pi BRCA1 BRCA2
1 .961 .015 .947
2 .974 .011 .964
3 .953 .010 .943
4 .883 .072 .817
5 .803 .064 .741
NOTE.—The pedigree is modified
compared with that shown in figure 5;
here the father of the proband has breast
cancer at age 70 years, and the mother
of the proband is free of cancer.
Table 4
Posterior Probabilities for Members of Family 2, in Five Scenarios
Given in Table 1
SCENARIO
AND TYPE OF
PROBABILITY
PROBABILITY FOR FAMILY MEMBER
1 2 3 4 5 6
1:
∗pi .035 .036 .007 .012 .025 .005
BRCA1 .017 .018 .002 .005 .019 .003
BRCA2 .018 .017 .005 .007 .005 .002
2:
∗pi .040 .041 .008 .013 .035 .006
BRCA1 .015 .016 .001 .004 .026 .003
BRCA2 .025 .025 .006 .009 .009 .003
3:
∗pi .021 .021 .004 .007 .019 .003
BRCA1 .008 .008 .0008 .002 .013 .002
BRCA2 .013 .013 .003 .005 .005 .001
4:
∗pi .085 .089 .025 .034 .039 .011
BRCA1 .058 .062 .013 .021 .032 .008
BRCA2 .026 .027 .012 .012 .007 .003
5:
∗pi .047 .049 .014 .019 .021 .006
BRCA1 .032 .034 .007 .012 .018 .004
BRCA2 .014 .015 .006 .007 .004 .002
Figure 8 Probabilistic sensitivity analysis, family 2. Boxplots represent the distribution of the probability that family member 1 of family
2 carries a mutation of BRCA1 or BRCA2, with her age being allowed to change. Each boxplot is based on the same Monte Carlo sample of
size 100. The variability is due to uncertainty in the cancer rates and in the allele frequency.
not available, and our own uncertainty assessment is
based on a comparison with BRCA1. The assumed dis-
tributions of allele frequencies of BRCA1 and BRCA2
are shown in figure 4. Although the proportion of fam-
ilies whose cancer is explained by BRCA2 is lower, given
the difference in penetrance, it is possible that the fre-
quency of BRCA2 is similar to or even greater than that
of BRCA1. Under the assumptions used in figure 4, there
is a probability of ∼10% that the frequency of BRCA2
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Table 5
Posterior Probabilities for Member 1
of Family 2, in Five Scenarios Given in
Table 1, When 30-Year-Old Niece Is
Assumed to Have Had Breast Cancer
at Age 30 Years
SCENARIO
PROBABILITY
∗pi BRCA1 BRCA2
1 .256 .164 .092
2 .284 .148 .135
3 .167 .088 .078
4 .414 .347 .067
5 .276 .232 .044
Table 7
Posterior Probabilities for Member 1
of Family 2, in Five Scenarios Given in
Table 1, When 38-Year-old Niece Is
Assumed to Have Had Breast Cancer
at Age 30 Years
SCENARIO
PROBABILITY
p* BRCA1 BRCA2
1 .130 .062 .068
2 .140 .047 .093
3 .075 .026 .050
4 .289 .218 .071
5 .177 .134 .043
Table 8
Posterior Probabilities for Members of
Family 2, in Five Scenarios Given in
Table 1, When 40-Year-old Niece Is
Assumed to Have Had Breast Cancer
at Age 30 Years
SCENARIO
PROBABILITY
p* BRCA1 BRCA2
1 .393 .260 .133
2 .429 .232 .197
3 .277 .152 .125
4 .557 .478 .079
5 .411 .353 .057
Table 6
Posterior Probabilities for Member 1
of Family 2, in Five Scenarios Given in
Table 1, When 38-Year-old Niece Is
Assumed to Have Had Breast Cancer
at Age 38 Years
SCENARIO
PROBABILITY
p* BRCA1 BRCA2
1 .100 .041 .059
2 .112 .032 .080
3 .060 .017 .042
4 .217 .151 .066
5 .128 .089 .039
is greater than that of BRCA1. Cancer rates for the gen-
eral population are based on large datasets, and the un-
certainty about their values can be ignored.
Results
In this section we illustrate our approach by using two
family pedigrees arising from actual counseling experi-
ence in the Duke Specialized Program of Research Ex-
cellence in breast cancer. We also consider small hypo-
thetical variations of each pedigree, to show the effect
on the probabilities that mutations are carried. The ped-
igrees are shown in figures 5 and 6.
For each family, we performed the computations un-
der five different scenarios for the penetrance and prev-
alence parameters. These scenarios are specified in table
1. The baseline scenario corresponds to the best esti-
mates of the parameters, based on the discussion in the
Evidence subsection. We also performed a probabilistic
analysis, using the distributions obtained in the Evidence
subsection.
We begin with family 1, focusing on the woman in-
dicated by the arrow. The probabilities that she carries
mutations are shown in table 2. Both the occurrence of
bilateral breast cancer and the high number of cases in
the family strongly suggest the presence of a mutation.
As a result of the clear line of descent, the probability
that she carries either mutation does not change signif-
icantly over the different scenarios. However, the prob-
abilities allocated to BRCA1 mutations and to BRCA2
mutations change more markedly. In the high-pene-
trance scenarios, BRCA2 becomes more likely than
BRCA1. This is because, with a higher penetrance for
both genes, the ovarian cancer cases and the healthy
cases give less support to BRCA1, compared with the
baseline case.
We now consider a modified pedigree for family 1, in
which the father of the proband had breast cancer at
age 70 years and in which the mother is free of cancer.
Table 3 shows the results. The presence of a case of male
breast cancer helps discriminate between BRCA1 and
BRCA2, which receives a high probability.
Figure 7 shows a probabilistic sensitivity analysis of
the same calculations, based on the distributions dis-
cussed in the Results section. Boxplots represent the dis-
tribution of the probability that family member 1 carries
a mutation of BRCA1 or BRCA2, with her age at onset
being allowed to change. The horizontal axis indicates
the age at onset of the first cancer. The second cancer is
assumed to follow 3 years later. Each boxplot is based
on the same Monte Carlo sample of size 100. The var-
iability is due to uncertainty both in the cancer rates and
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Table 9
Posterior Probabilities for Member 1
of Family 2, in Five Scenarios Given in
Table 1, When No Data Regarding
Mother’s Age or Cancer Status Are
Assumed to Have Been Available
SCENARIO
PROBABILITY
p* BRCA1 BRCA2
1 .236 .191 .045
2 .319 .246 .074
3 .195 .151 .045
4 .266 .233 .032
5 .162 .143 .019
Figure 10 Probabilistic sensitivity analysis of the cumulative
risks breast and ovarian cancer for a woman with the family history
of members 3 and 4 of family 2. Each boxplot is based on the same
Monte Carlo sample of size 100.
Figure 9 Cumulative risk of breast cancer for a woman with
the family history of members 3 and 4 of family 2. The black dots
represent predictions based on our model. The letters “C” represent
predictions based on the model of Claus et al. (1994).
in allele frequency. Late onset decreases the overall prob-
ability that the individual carries a mutation. The pres-
ence of a male breast cancer case is a strong indication
that the mutation could be at BRCA2. When the age at
onset is 30 years, BRCA1 becomes comparatively more
likely, and uncertainty about which of the two candidate
genes is mutated becomes larger.
Consider now family 2. For the family members with
cancer, we do not know either the ages at the time of
the present study or the ages at death, and so, with
regard to the other cancers of interest, we censored them
at the time of their known cancer. For example, formem-
ber 1, we used the information that she was free of
ovarian cancer at age 49 years. The age of the sister-in-
law of family members 1–4 is unknown and, in any case,
has little effect on the calculations, because her daughter
is quite young.
When we focus on family members 1–4, there is little
evidence of a mutation on their father’s side of the fam-
ily, except for the cancer in family members 1 and 2;
there is only slightly more evidence on their mother’s
side. The maternal aunt with breast cancer (BC39) is
evidence for a mutation; but the mother was free of both
breast cancer and ovarian cancer when she died at age
78 years, and this happens for !5% of carriers of
BRCA1. The mother’s disease-free status substantially
weakens the link between the cancers of the maternal
aunt and those of of family members 1 and 2. The result
is that family members 1–4 have moderate probabilities
of mutations. From the data shown in table 4, in the
baseline scenario, it can be seen that a BRCA2 mutation
is more likely than a BRCA1 mutation. This is the result
of both the lack of ovarian cancer cases and the relatively
late onset of the breast cancer cases. Decreasing the pen-
etrance parameters leads to a more prominent role of
the maternal aunt, resulting in an increased probability
of mutation, with BRCA1 increasing more than BRCA2,
because of the early onset. However, the probability that
an individual carries a mutation is not monotonic in the
penetrance. When the penetrance of only BRCA1 is var-
ied, the probability of a BRCA1mutation reaches amax-
imum at a penetrance of ∼.5.
Figure 8 shows a probabilistic sensitivity analysis of
the same calculations, again based on the distributions
discussed in the Evidence subsection. Boxplots represent
the distribution of the probability that family member
1 carries a mutation of BRCA1 or BRCA2, with her
mother’s age at death being allowed to change. Decreas-
ing the mother’s age at death also leads to a more prom-
inent role of the maternal aunt, with BRCA1 changing
more than BRCA2, because of the early onset of the
aunt’s cancer.
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It is also interesting to focus on the probability, p*,
that family member 1 is a carrier and to consider hy-
pothetical changes in the cancer status of other family
members. We begin by assuming that the 30-year-old
niece had breast cancer at age 30 years; then the prob-
abilities are those given in table 5, showing a very sub-
stantial increase.
If the 38-year-old niece (family member 6) had breast
cancer at age 38 years, then the probabilities are those
given in table 6. The impact on p* is smaller than it is
for the probabilities given in table 5, for two reasons:
the older age makes it less likely that breast cancer is
due to BRCA1, and the niece’s mother is disease free at
age 58 years and is therefore less likely to carry the
mutation than are the parents of the 30-year-old niece,
about whom nothing is known.
To separate the two effects, assume that the 38-year-
old niece had breast cancer at age 30 years. Then the
probabilities are those given in table 7.
Next, assume that the 40-year-old niece (family mem-
ber 5) had breast cancer at age 30 years. Then, the prob-
abilities are those given in table 8, which is so large
because the 40-year-old niece’s mother had ovarian
cancer.
Finally, consider the case in which no information
about either the mother’s age or her cancer status was
available; the results are given in table 9. This strength-
ens the contribution of the maternal aunt, greatly in-
creasing p*.
Our model can be used to make predictions about the
occurrence of cancer in healthy family members. The
predicted cancer rate R (either breast cancer or ovarian
cancer or both) at age a is
R(aFfam.hist.) 
2 2 P[BRCA1  i , BRCA2  i Ffam.hist.]1 2
i 0 i 01 2
R(aFBRCA1  i , BRCA2  i ) .1 2
Using this expression, we can compare our model’s re-
sults against the similar predictions provided by Claus
et al. (1994, table 4). We focus on family 2. Because
Claus et al. (1994) consider only breast cancer, we mod-
ified family 2 by assuming that family member 2 had
breast cancer rather than ovarian cancer. A comparison
of the cumulative incidence curves for an individual with
the same family history as has been presented for family
members 3 and 4 is shown in figure 9. In this case, the
predictions based on our model are lower than those of
Claus et al., primarily as the result of the large number
of unaffected members in the pedigree. We also per-
formed a probabilistic sensitivity analysis of the same
predictions, on the basis of the distributions discussed
in the Evidence subsection. The results, for both breast
cancer and ovarian cancer, are shown in figure 10.
Discussion
In this paper we have discussed a model for evaluating
the probability that a woman is a carrier of a genetic
mutation in the BRCA1 and BRCA2 genes, on the basis
of her family’s history of breast cancer and ovarian can-
cer in first- and second-degree relatives. We use a Bay-
esian approach to incorporate both the uncertainty
about family members’ genetic status and the uncer-
tainty about the prevalence of the mutation in the pop-
ulation and about the cancer rates for carriers.
Our model is currently being used in a randomized
trial comparing tailored material to standard printed
material, in genetic counseling. Women in the tailored-
information arm receive estimates of the probability that
they carry a mutation of BRCA1 or BRCA2, computed
on the basis of the model described here. The infor-
mation is presented in graphical (pie chart), numerical,
or verbal format, depending on patient preference.
Counselees are provided with a range of probabilities
reflecting uncertainty about the genetic parameters, ob-
tained according to the procedure discussed in the Un-
certainty about Genetic Parameters subsection. The soft-
ware used to perform the calculations is available to
interested investigators, for noncommercial purposes;
thus far, it has been licensed to sites that are using it in
counseling and in genetic epidemiology research.
The penetrance and prevalences used by the model are
stored in an external file, which is input to the program.
In this way, it is convenient to create customized com-
putations for subpopulations with different genetic par-
ameters. For example, recent investigations (e.g., Od-
doux et al. 1996; Roa et al. 1996; Struewing et al. 1997)
suggest that mutations that are specific to the Ashkenazi
Jewish population may be associated with prevalence
and penetrance functions different from those reported
by Easton and colleagues. We have developed an anal-
ysis, parallel to that described here, that can be used in
counseling women of Ashkenazi Jewish ancestry.
We have considered BRCA1 and BRCA2 and regard
all other breast cancer as being sporadic. This is a lim-
itation of our model, since additional breast cancer genes
or ovarian cancer genes may exist (Ha˚kansson et al.
1997; Vehmanen et al. 1997). Including other genes and
considering all other breast and ovarian cancer as being
sporadic would give a different probability—usually
smaller—that a woman carries BRCA1 and BRCA2. It
would also give a different probability—larger—that a
counseland carries at least one mutation in one or more
breast cancer genes. Our procedure can be modified to
include additional genes; however, such a modification
would require information, not yet available, about the
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age-specific incidence of breast cancer and ovarian can-
cer resulting from such genes.
Spontaneous mutations of BRCA1 and BRCA2 are
not currently incorporated in our model, again because
of the lack of relevant empirical evidence. In the presence
of spontaneous mutations, the probability that an in-
dividual carries a mutation is higher than our model
predicts for cancer cases and is lower than our model
predicts for noncancer cases. Also, compared with our
results, the possibility of spontaneous mutations reduces
the predictive power of the family history.
Environmental or other factors may modify the sus-
ceptibility to cancer, in carriers of mutations. A model
explicitly incorporating such individual covariate infor-
mation is likely to perform better that ours. In family
2, discussed in this section, additional covariate infor-
mation may help us to infer the genetic status of the
mother, a key element in the calculation. Was she a car-
rier exposed to factors either delaying onset or pre-
venting cancer from developing? Unfortunately, again,
knowledge about relevant factors is, at present, insuf-
ficient for quantitative analysis of this kind of question.
Although important, all these limitations are rooted
in uncertainties regarding familial breast cancer. We ex-
pect important progress in this area in the near future.
Models tailored to the new information could then be
developed by means of the approach outlined here.
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Appendix
Description of the Program Used for Calculation of the
Expression P[fam. hist.FBRCA1,BRCA2]
The structure of a pedigree, including information on
first- and second-degree relatives of a given counseland
individual, is specified by the following quantities: the
number of siblings, ns; the number of mother’s siblings,
na; the number of father’s siblings, nA; the number of
offspring, nd; and the number of offspring of sibling t,
n(t), where . For each family member, thet  1,) ,ns
contribution to the likelihood function depends on the
age a; the genetic status of BRCA1, i; the genetic status
of BRCA2, j; and the disease status. We denote by
and the cumulative incidence curves forij ijR (a) R (a)B O
breast cancer and ovarian cancer, respectively, and we
denote by r the incidence curve, or the first derivative
of R. For member m, since breast cancer incidence and
ovarian cancer incidence are assumed to be independent,
conditional on genetic status, the conditional probability
of disease history, given genetic status, , factors intoijrm
two disease-specific terms, as , whereij B,ij O,ijr  r rm m m
ijr (a) if m had ovarian cancer at aOO,ijr m ij{1R (a) if m was free of ovarian cancer until aO
and is defined similarly, with the exception of theB,ijrm
possible adjustment for bilateral breast cancer, as de-
scribed in the Methods section.
Incorporation of each member’s contribution is based
on two basic building blocks: updating of data on off-
spring, given data on their parents (implemented by the
d functions, for downward), and updating of data on
parents, given data on their offspring (implemented by
the u functions, for upward). The downward updates
will be applied, in turn, to each of the counseland’s off-
spring, to siblings and their offspring, and to parents’
siblings. The upward update will be applied to the
counseland, to her parents, and to her grandparents. The
computation of likelihood function requires a recursive
use of these functions, as described below.
To define the basic downward function for a generic
group of offspring of the same parents, let m1 and m2
be the BRCA1 genetic status and the BRCA2 genetic
status of the offspring’s mother, and let f1 and f2 be the
BRCA1 genetic status and the BRCA2 genetic status of
the offspring’s father. Then, the downward step is
d(m ,m , f , f ,n) 1 2 1 2
2 2
n ij  r P[iFm , f ]P[jFm , f ] .m1 m 1 1 2 2
i0 j0
Here, the subscript m ranges over the set of siblings of
the same parents, and the argument n can take values
nd, na, nA, or n(t).
The contribution of the counseland’s siblings, given
both the genetic status of the counseland’s mother and
the genetic status of the counseland’s father, is then
d (m ,m , f , f ) S 1 2 1 2
2 2
ns ij  r P[iFm , f ]P[jFm , f ]m1 m 1 1 2 2
i0 j0
2 2
ij [ ] r P[k, l]d i, j,k, l,n(t) ,q(m)
k0 l0
wherem ranges over the set of counseland’s siblings and
q(m) indicates the corresponding mate. If there are no
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offspring of sibling t, then , , and ijn(t)  0 d  1 r q(m)
. The expression above assumes that no family history1
is available for the siblings’ mates.
The information about the counseland’s parents and
grandparents will be incorporated via the upward struc-
ture. For both the maternal and paternal grandparents,
we use
u (o , o ) G 1 2
2 2 2 2
ij kl r rm m1 2
i0 j0 k0 l0
P[i,kFo ]P[j, lFo ]d(i, j,k, l,n) ,1 2
where m1,m2 is a pair of grandparents. andP[i,kFo ]1
are calculated as was calculated in theP[j, lFo ] P[m, fFo]2
Updating subsection. These functions can be used to
incorporate the contribution of the counseland’s parents,
given the counseland’s own genetic status; as above, this
is described by the variables BRCA1 and BRCA2. Then
u (BRCA1, BRCA2) p
2 2 2 2
ij kl r rm m1 2
i0 j0 k0 l0
P[i,kFBRCA1]P[j, lFBRCA2]d (i, j,k, l)u (i,k)u (j, l) ,S g g
where m1,m2 are the counseland’s parents. Finally, we
can combine all of these expressions and incorporate the
information on the counseland by means of
P[family historyFBRCA1  i, BRCA2  j]
2 2
ij ij r u (i, j) r P[k, l]d(i, j,k, l,n ) ,m p q(m) d
k0 l0
for . Here, m is the counseland, and q(m) isi, j  0, 1, 2
the counseland’s mate.
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